MAIA MAIA Biotech: Enterprise Value-to-Revenue Multiple

Public company logo of MAIABiotech.com (MAIA)

MAIA Biotechnology is optimizing biomaterial supplies to protect margins, which is supported by the market value-to-revenue valuation. The value of 0.00 determines the current magnitude of the indicator on the chart. Patents in telomere therapy provide potential pricing power. Meanwhile, the localization of development in the US and the humanitarian status of medicine completely neutralize geopolitical threats to the assets.

Company Value to Revenue: MAIA Biotech (MAIA) for 11/23/2025 - 11/20/2026

MAIABiotech.com - analytical breakdowns and key metrics (MAIA)

- share price and consensus valuation forecast:
Initial company analysis:MAIA Biotechnology MAIA
Product sample of MAIA Biotechnology

For MAIA Biotechnology, whose telomerase inhibitor developments are in early stages and generate no commercial revenue, the EV/Sales ratio reflects purely speculative market expectations. This metric compares the total enterprise value (market capitalization plus net debt) to annual revenue, allowing investors to assess the premium paid for the company's future prospects in the absence of current pricing power.

Competitor analysis for MAIA Biotechnology

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP